<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23649971</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>01</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1179-1950</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>73</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Drugs</Title>
<ISOAbbreviation>Drugs</ISOAbbreviation>
</Journal>
<ArticleTitle>Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.</ArticleTitle>
<Pagination>
<MedlinePgn>767-77</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-013-0049-8</ELocationID>
<Abstract>
<AbstractText>Previously characterized by a median overall survival of between 6 and 12Â months, metastatic melanoma now has a number of novel and effective treatment options. The ability to target the mitogen-activated protein kinase (MAPK) pathway with BRAF (v-raf murine sarcoma viral oncogene homolog B1) or MEK (mitogen-activated protein kinase kinase) inhibitors can result in rapid clinical benefit, but is too often associated with limited durability of response. Resistance inevitably develops either via reactivation of the MAPK pathway or via bypass signalling pathways, such as the PI3K (phosphoinositide 3-kinase) pathway. Combination strategies are thus appealing with an aim to overcome potential resistance mechanisms. Already, the combination of the BRAF inhibitor, dabrafenib, along with the MEK inhibitor, trametinib, has shown promising results clinically and with an improved toxicity profile. Other combination strategies with agents that target the PI3K pathway, angiogenesis, and the immune system are in development or already underway, although potential overlapping toxicities require close monitoring. The currently available molecularly targeted agents that target the MAPK pathway and development of combination therapies for treatment of metastatic melanoma are discussed in further detail.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lemech</LastName>
<ForeName>Charlotte</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Sarah Cannon Research UK, 93 Harley St, London W1G 6AD, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Infante</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Arkenau</LastName>
<ForeName>Hendrik-Tobias</ForeName>
<Initials>HT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>New Zealand</Country>
<MedlineTA>Drugs</MedlineTA>
<NlmUniqueID>7600076</NlmUniqueID>
<ISSNLinking>0012-6667</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23649971</ArticleId>
<ArticleId IdType="doi">10.1007/s40265-013-0049-8</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Nature. 2011 Nov 23;480(7377):387-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22113612</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pigment Cell Melanoma Res. 2012 Mar;25(2):248-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22171948</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2012 Mar 22;12(4):237-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22437869</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2011 Apr;2(4):336-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21505228</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2008 May 1;68(9):3429-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18451171</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Oncol. 2008 Apr;1(4):395-405</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19383313</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 Jul 1;70(13):5213-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20551059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2006 May;5(5):1136-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16731745</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Feb 23;366(8):707-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22356324</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jul 12;367 (2):107-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22663011</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Med. 2012 Aug;18(8):1239-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22820643</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2010 Dec 16;468(7326):968-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21107320</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2011 Jun 8;305(22):2327-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21642685</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2008 May 1;26(13):2139-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18390968</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2008 Jun 15;68(12):4853-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18559533</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jan 19;366(3):207-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22256804</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jun 28;366(26):2443-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22658127</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2002 Jun 27;417(6892):949-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12068308</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Nov 17;353(20):2135-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16291983</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2012 Apr;11(4):909-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22389471</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2005 Oct;5(10):761-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16175177</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2010 Dec 15;16(24):6040-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21169256</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2006 Sep 10;24(26):4340-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16908931</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2010 Aug 26;363(9):809-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20818844</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Commun. 2012 Mar 06;3:724</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22395615</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2010 Mar 18;464(7287):427-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20179705</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ther Adv Med Oncol. 2012 Mar;4(2):61-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22423265</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Apr 1;29(10):1239-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21343559</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2010 Aug 19;363(8):711-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20525992</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2010 Mar 18;464(7287):431-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20130576</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Feb 1;31(4):499-506</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23248252</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2013 Mar;14(3):249-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23414587</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Immunol Immunother. 2009 May;58(5):823-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19198837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Invest Dermatol. 2004 Dec;123(6):1151-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15610528</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Aug 1;29(22):3085-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21383288</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2012 May 1;18(9):2502-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22351686</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2011 Jun 30;364(26):2517-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21639810</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Feb 1;31(4):482-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23248257</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Transl Med. 2010 Jul 14;8:67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20630094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Chromosomes Cancer. 2010 Aug;49(8):733-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20544847</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2004 Mar 19;116(6):855-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15035987</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2011 Jun 30;364(26):2507-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21639808</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Med Insights Oncol. 2012;6:53-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22253555</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer J. 2011 Nov-Dec;17(6):505-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22157295</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2012 Jul 28;380(9839):358-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22735384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2011 Apr 1;71(7):2750-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21317224</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2012 May 19;379(9829):1893-901</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22608338</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19915144</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2010 Nov 16;18(5):485-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21035406</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2008 Sep;7(9):2876-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18790768</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2009 Jan 8;28(1):85-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18794803</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2010 Dec 14;18(6):683-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21156289</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Mar 8;366(10 ):925-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22397654</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2010 Jan 22;140(2):209-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20141835</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Nov;367 (18):1694-703</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23020132</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jun 28;366(26):2455-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22658128</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2010 Dec 16;468(7326):973-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21107323</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2012 Aug;13(8):773-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22805291</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>